Trials / Completed
CompletedNCT01045603
Instanyl® Non-Interventional Study
A 3 Month Observational Prospective Patient Cohort Study of the Treatment of Breakthrough Pain in Cancer Patients With Instanyl®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 309 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to describe the use of Instanyl® (Intranasal fentanyl spray) in the treatment of breakthrough pain (BTP) in cancer patients by success of dose titration and distribution of dose strength. Data will be collected at three different time points over a 3 month period.
Conditions
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2010-01-11
- Last updated
- 2012-10-29
Locations
65 sites across 7 countries: Denmark, France, Greece, Ireland, Norway, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT01045603. Inclusion in this directory is not an endorsement.